FOXO1 and neoplasm: Both genetic and pharmacological inhibition of FOXO1 in CAR T cells results in a more exhausted phenotype and weakened anti-tumor responses, while overexpression of FOXO1 enhances anti-tumor immunity, increases mitochondrial mass and induces more stemness [49, 50].